{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:24:19Z","timestamp":1792081459355,"version":"4.4.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.tjpad.2025.100092","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T07:40:16Z","timestamp":1739346016000},"page":"100092","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Diagnostic and discriminative accuracy of plasma phosphorylated tau 217 for symptomatic Alzheimer\u02bcs disease in a Chinese cohort"],"prefix":"10.1016","volume":"12","author":[{"given":"Li-Min","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dequan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dian","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9675-5322","authenticated-orcid":false,"given":"Nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.tjpad.2025.100092_bib0001","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jalz.2007.04.381","article-title":"Forecasting the global burden of Alzheimer's disease","volume":"3","author":"Brookmeyer","year":"2007","journal-title":"Alzheimers Dement"},{"issue":"10","key":"10.1016\/j.tjpad.2025.100092_bib0002","first-page":"965","article-title":"Promising results in 18-month analysis of alzheimer drug candidate","volume":"320","author":"Abbasi","year":"2018","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.tjpad.2025.100092_bib0003","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.jalz.2016.10.001","article-title":"The crisis in recruitment for clinical trials in Alzheimer's and dementia: an action plan for solutions","volume":"12","author":"Fargo","year":"2016","journal-title":"Alzheimers Dement"},{"issue":"12","key":"10.1016\/j.tjpad.2025.100092_bib0004","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","article-title":"Differential roles of Abeta42\/40, p-tau231 and p-tau217 for Alzheimer's trial selection and disease monitoring","volume":"28","author":"Ashton","year":"2022","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100092_bib0005","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/s41591-021-01348-z","article-title":"Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures","volume":"27","author":"Palmqvist","year":"2021","journal-title":"Nat Med"},{"issue":"7691","key":"10.1016\/j.tjpad.2025.100092_bib0006","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-beta biomarkers for Alzheimer's disease","volume":"554","author":"Nakamura","year":"2018","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.tjpad.2025.100092_bib0007","doi-asserted-by":"crossref","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","article-title":"High-precision plasma beta-amyloid 42\/40 predicts current and future brain amyloidosis","volume":"93","author":"Schindler","year":"2019","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.tjpad.2025.100092_bib0008","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/alz.12841","article-title":"Plasma and CSF biomarkers in a memory clinic: head-to-head comparison of phosphorylated tau immunoassays","volume":"19","author":"Ashton","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"11","key":"10.1016\/j.tjpad.2025.100092_bib0009","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1001\/jamaneurol.2021.3180","article-title":"Head-to-head comparison of 8 plasma amyloid-beta 42\/40 assays in Alzheimer disease","volume":"78","author":"Janelidze","year":"2021","journal-title":"JAMA Neurol"},{"issue":"5","key":"10.1016\/j.tjpad.2025.100092_bib0010","doi-asserted-by":"crossref","first-page":"e671","DOI":"10.1212\/WNL.0000000000011226","article-title":"Plasma Tau and neurofilament light in frontotemporal lobar degeneration and alzheimer disease","volume":"96","author":"Illan-Gala","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.tjpad.2025.100092_bib0011","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.dadm.2017.07.004","article-title":"Plasma amyloid beta 42\/40 ratios as biomarkers for amyloid beta cerebral deposition in cognitively normal individuals","volume":"8","author":"Fandos","year":"2017","journal-title":"Alzheimers Dement (Amst)"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100092_bib0012","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3233\/JAD-161114","article-title":"Plasma Tau association with brain atrophy in mild cognitive impairment and Alzheimer's disease","volume":"58","author":"Deters","year":"2017","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100092_bib0013","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","article-title":"Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology","volume":"81","author":"Ashton","year":"2024","journal-title":"JAMA Neurol"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100092_bib0014","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","article-title":"Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration","volume":"26","author":"Thijssen","year":"2020","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.tjpad.2025.100092_bib0015","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs. other neurodegenerative disorders","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100092_bib0016","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","article-title":"Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia","volume":"26","author":"Janelidze","year":"2020","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100092_bib0017","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/brain\/awac333","article-title":"Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease","volume":"146","author":"Janelidze","year":"2023","journal-title":"Brain"},{"issue":"9","key":"10.1016\/j.tjpad.2025.100092_bib0018","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","article-title":"Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study","volume":"20","author":"Thijssen","year":"2021","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100092_bib0019","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Ageing-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100092_bib0020","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","article-title":"Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria","volume":"13","author":"Dubois","year":"2014","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100092_bib0021","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2796.2004.01388.x","article-title":"Mild cognitive impairment as a diagnostic entity","volume":"256","author":"Petersen","year":"2004","journal-title":"J Intern Med"},{"issue":"Pt 9","key":"10.1016\/j.tjpad.2025.100092_bib0022","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1093\/brain\/awr179","article-title":"Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia","volume":"134","author":"Rascovsky","year":"2011","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.tjpad.2025.100092_bib0023","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","article-title":"Classification of primary progressive aphasia and its variants","volume":"76","author":"Gorno-Tempini","year":"2011","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100092_bib0024","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/WAD.0000000000000034","article-title":"Diagnostic criteria for vascular cognitive disorders: a VASCOG statement","volume":"28","author":"Sachdev","year":"2014","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100092_bib0025","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13195-023-01222-9","article-title":"The identification and cognitive correlation of perfusion patterns measured with arterial spin labelling MRI in Alzheimer's disease","volume":"15","author":"Meng","year":"2023","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100092_bib0026","doi-asserted-by":"crossref","first-page":"e5900","DOI":"10.1002\/gps.5900","article-title":"A neuropsychological profile and its correlation with neuroimaging markers in patients with subcortical ischaemic vascular dementia","volume":"38","author":"Tian","year":"2023","journal-title":"Int J Geriatr Psychiatry"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100092_bib0027","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13195-023-01246-1","article-title":"Reference intervals for plasma amyloid-beta, total tau, and phosphorylated tau181 in healthy elderly Chinese individuals without cognitive impairment","volume":"15","author":"Chen","year":"2023","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100092_bib0028","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1002\/alz.13722","article-title":"The Bio-Hermes Study: biomarker database developed to investigate blood-based and digital biomarkers in community-based, diverse populations clinically screened for Alzheimer's disease","volume":"20","author":"Mohs","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"10","key":"10.1016\/j.tjpad.2025.100092_bib0029","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/acn3.51863","article-title":"A blood biomarker test for brain amyloid impacts the clinical evaluation of cognitive impairment","volume":"10","author":"Monane","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100092_bib0030","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jalz.2014.07.001","article-title":"Plasma amyloid-beta and risk of Alzheimer's disease in the Framingham Heart Study","volume":"11","author":"Chouraki","year":"2015","journal-title":"Alzheimers Dement"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100092_bib0031","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/alz.12447","article-title":"Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease","volume":"18","author":"Chatterjee","year":"2022","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100092_bib0032","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","article-title":"Cerebrospinal fluid and plasma biomarkers in Alzheimer disease","volume":"6","author":"Blennow","year":"2010","journal-title":"Nat Rev Neurol"},{"issue":"17","key":"10.1016\/j.tjpad.2025.100092_bib0033","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1212\/WNL.0000000000003246","article-title":"Plasma tau in Alzheimer disease","volume":"87","author":"Mattsson","year":"2016","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.tjpad.2025.100092_bib0034","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.tins.2020.04.007","article-title":"Resurrecting the mysteries of big Tau","volume":"43","author":"Fischer","year":"2020","journal-title":"Trends Neurosci"},{"issue":"11","key":"10.1016\/j.tjpad.2025.100092_bib0035","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200861","article-title":"Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer's disease","volume":"217","author":"Barthelemy","year":"2020","journal-title":"J Exp Med"},{"issue":"8","key":"10.1016\/j.tjpad.2025.100092_bib0036","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/alz.12301","article-title":"Plasma p-tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multiethnic, community study","volume":"17","author":"Brickman","year":"2021","journal-title":"Alzheimers Dement"},{"issue":"8","key":"10.1016\/j.tjpad.2025.100092_bib0037","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrneurol.2015.119","article-title":"Clearance systems in the brain-implications for Alzheimer disease","volume":"11","author":"Tarasoff-Conway","year":"2015","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100092_bib0038","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/nn.4489","article-title":"Pericyte degeneration leads to neurovascular uncoupling and limits oxygen supply to brain","volume":"20","author":"Kisler","year":"2017","journal-title":"Nat Neurosci"},{"issue":"7","key":"10.1016\/j.tjpad.2025.100092_bib0039","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1093\/brain\/awx112","article-title":"Cerebrovascular resistance: effects on cognitive decline, cortical atrophy, and progression to dementia","volume":"140","author":"Yew","year":"2017","journal-title":"Brain"},{"issue":"9882","key":"10.1016\/j.tjpad.2025.100092_bib0040","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1016\/S0140-6736(13)60221-4","article-title":"Epidemiology of Alzheimer's disease and other forms of dementia in China, 1990-2010: a systematic review and analysis","volume":"381","author":"Chan","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.tjpad.2025.100092_bib0041","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.949129","article-title":"Contribution of blood\u2012brain barrier-related blood-borne factors for Alzheimer's disease vs. vascular dementia diagnosis: a pilot study","volume":"16","author":"Gong","year":"2022","journal-title":"Front Neurosci"},{"issue":"9","key":"10.1016\/j.tjpad.2025.100092_bib0042","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/WNR.0b013e328326f82f","article-title":"B-type natriuretic peptide plasma levels are elevated in subcortical vascular dementia","volume":"20","author":"Kondziella","year":"2009","journal-title":"Neuroreport"},{"issue":"8","key":"10.1016\/j.tjpad.2025.100092_bib0043","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1002\/alz.12974","article-title":"Placental growth factor as a sensitive biomarker for vascular cognitive impairment","volume":"19","author":"Hinman","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"9","key":"10.1016\/j.tjpad.2025.100092_bib0044","first-page":"1797","article-title":"Plasma p-tau231 and p-tau217 as state markers of amyloid-beta pathology in preclinical Alzheimer's disease","volume":"28","author":"Mila-Aloma","year":"2022","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100092_bib0045","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/alz.12395","article-title":"Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Abeta42\/Abeta40 and p-tau","volume":"18","author":"Janelidze","year":"2022","journal-title":"Alzheimers Dement"},{"issue":"11","key":"10.1016\/j.tjpad.2025.100092_bib0046","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1001\/jama.2018.12917","article-title":"Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs. other neurodegenerative disorders","volume":"320","author":"Ossenkoppele","year":"2018","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.tjpad.2025.100092_bib0047","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jamaneurol.2017.4907","article-title":"Association between amyloid and tau accumulation in young adults with autosomal dominant Alzheimer disease","volume":"75","author":"Quiroz","year":"2018","journal-title":"JAMA Neurol"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100092_bib0048","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41591-020-0781-z","article-title":"A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease","volume":"26","author":"Barthelemy","year":"2020","journal-title":"Nat Med"},{"issue":"16","key":"10.1016\/j.tjpad.2025.100092_bib0049","doi-asserted-by":"crossref","first-page":"eaaz2387","DOI":"10.1126\/sciadv.aaz2387","article-title":"Abeta deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease","volume":"6","author":"Mattsson-Carlgren","year":"2020","journal-title":"Sci Adv"},{"key":"10.1016\/j.tjpad.2025.100092_bib0050","article-title":"Prediction of future cognitive decline among cognitively unimpaired individuals using measures of soluble phosphorylated tau or tau tangle pathology","author":"Ossenkoppele","year":"2024","journal-title":"medRxiv"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100092_bib0051","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100092_bib0052","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/alz.12787","article-title":"Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance","volume":"19","author":"Pichet","year":"2023","journal-title":"Alzheimers Dement"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580725000366?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580725000366?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T13:39:30Z","timestamp":1786023570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580725000366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2274580725000366"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100092","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnostic and discriminative accuracy of plasma phosphorylated tau 217 for symptomatic Alzheimer\u02bcs disease in a Chinese cohort","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100092","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100092"}}